Pharmaceuticals, Biotechnology and Life Sciences
Additional analyses examine the impact of migraine in France, Spain and the United Kingdom TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries…
PXL770, a novel direct AMPK activator, produced additive benefits in a NASH model when combined with other late-stage agents in…
LYON, France–(BUSINESS WIRE)–POXEL S.A. (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for…
Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE) trial met both of its co-primary endpoints.
Ipsen’s results reveal the need for longer-lasting symptoms control to improve patients’ perceived quality of life
AbCellera will use its world-leading antibody drug discovery platform in a multi-year collaboration to identify antibodies against up to nine targets
Tricida estimates that the net proceeds from the offering will be approximately $193.0 million
Takeda’s Alunbrig long-Term results from the phase 3 ALTA 1L trial established Alunbrig as a superior first-line treatment compared to crizotinib for people with ALK+ metastatic NSCLC, including those with brain metastases.
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today that, due to public health and safety concerns related…
Advantech Capital and Vivo Capital have invested $15 million in Sinovac Research and Development Co., Ltd. (“Sinovac R&D”), a wholly owned subsidiary of Sinovac, to further the development of an inactivated vaccine against COVID-19 named CoronaVac.